federal_register: E8-19572

All Federal Register documents (rules, proposed rules, notices, presidential documents) from 1994 to present. Nearly 1M documents with full-text search.

This data as json

document_number title type abstract publication_date pub_year pub_month html_url pdf_url agency_names agency_ids excerpts
E8-19572 Supplemental Applications Proposing Labeling Changes for Approved Drugs, Biologics, and Medical Devices Rule The Food and Drug Administration (FDA) is amending its regulations regarding changes to an approved new drug application (NDA), biologics license application (BLA), or medical device premarket approval application (PMA). This final rule provides that a supplemental application submitted under certain FDA regulations is appropriate to amend the labeling for an approved product to reflect newly acquired information and to add or strengthen a contraindication, warning, precaution, or adverse reaction if there is sufficient evidence of a causal association with the drug, biologic, or device, as defined in other FDA regulations and guidance documents. 2008-08-22 2008 8 https://www.federalregister.gov/documents/2008/08/22/E8-19572/supplemental-applications-proposing-labeling-changes-for-approved-drugs-biologics-and-medical https://www.govinfo.gov/content/pkg/FR-2008-08-22/pdf/E8-19572.pdf Health and Human Services Department; Food and Drug Administration 221,199 The Food and Drug Administration (FDA) is amending its regulations regarding changes to an approved new drug application (NDA), biologics license application (BLA), or medical device premarket approval application (PMA). This final rule provides that a...

Links from other tables